Clinic Roundup
Oncothyreon Inc., of Seattle, said it enrolled the first patient in a Phase I trial of ONT-10, a therapeutic vaccine directed at MUC1. The study is designed to evaluate the safety and immunogenicity of the vaccine in patients with cancers that commonly express MUC1, including breast, non-small-cell lung, ovarian, colorectal, prostate, pancreatic and gastric cancers.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.